ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary

ADC Therapeutics SA

12/08/2025 14:32

ADC Therapeutics SA ADCT.N reported a quarterly adjusted loss of 38 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of six analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -65 cents to -36 cents per share.

Revenue rose 8.2% to $18.84 million from a year ago; analysts expected $17.86 million.

ADC Therapeutics SA's reported EPS for the quarter was a loss of 50 cents​.

The company reported a quarterly loss of $56.65 million.

ADC Therapeutics SA shares had held steady so far this quarter and gained 34.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 18.5% in the last three months.​

In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for ADC Therapeutics SA is $9.00, about 70.2% above its last closing price of $2.68

This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.47
-0.38
Beat
Mar. 31 2025
-0.40
-0.36
Beat
Dec. 31 2024
-0.41
-0.29
Beat
Sep. 30 2024
-0.39
-0.42
Missed